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Paraneoplastic Pemphigus Is a 
Life-Threatening Disease
Richard Lucas Konichi-Dias
Abstract
Paraneoplastic pemphigus is a multiorganic autoimmune disease, usually 
triggered by neoplasias, mainly of lymphoproliferative origin such as chronic 
lymphocytic leukemia, multiple myeloma, non-Hodgkin’s lymphoma, Castleman 
disease, and thymoma. This disorder is characterized by the presence of auto-
antibodies that react against proteins, such as desmoplakins, desmocollins, and 
others existing in cell junctions. The prognosis is reserved, and the mortality 
rate of the disease is very high, thus proving to be an additional challenge in 
the therapeutic management of onco-hematological diseases. The objective of 
this chapter is to solve the main clinical aspects of paraneoplastic pemphigus in 
lymphoproliferative hematological diseases, anatomopathological and immu-
nofluorescence characteristics, as well as associations with the main differential 
diagnoses and therapeutic management. We will also describe the main differen-
tial diagnoses of paraneoplastic pemphigus, such as various types of pemphigus 
including induced drug, bullous pemphigoid, drug eruption, lichen planus, 
graft versus host disease, erythema multiforme, Stevens-Johnson syndrome, and 
toxic epidermal necrolysis. In addition, the prognosis and quality of life will be 
mentioned.
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1. Introduction
Paraneoplastic pemphigus (PNP) was first described in 1990 by Anhalt et al. as 
a rare autoimmune disease that causes ulcerated lesions and vesicular eruptions in 
the mucocutaneous regions [1]. In 2001, the researcher Nguyen et al. introduced the 
term multiorganic autoimmune paraneoplastic syndrome, since it is a systemic dis-
ease that can affect the kidneys, bladder, and smooth and striated muscles [2]. PNP 
is a disease triggered mainly by B-cell lymphomas and malignant hematological 
diseases [3]. Other neoplasms also demonstrate the onset of this disease, as well as 
carcinoma of the stomach, lung, and colon [3]. The patients with PNP present high 
mortality rates, being around 90% of the cases, besides presenting an extremely 
complex and difficult diagnosis, since it resembles several other diseases [4, 5]. The 
treatment and management of this disease are often ineffective, as it is an extremely 
aggressive and lethal disease.
In this chapter, we will address the epidemiological aspects, the main triggers, 
pathophysiology, main manifestations, diagnosis, differential diagnoses, treatments 
used, prognosis, and the quality of life of patients affected by PNP.
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2. Epidemiology
Because PNP is an extremely rare disease, there is still no data on the incidence 
of this disease in the world population [3]. To date, about 500 cases have been 
reported in the literature, with PNP representing 3–5% of all cases of pemphigus 
in the population [6–8]. The vast majority of affected patients demonstrate lym-
phoproliferative disorders (LPD) [9]. Although this disease can affect children and 
adolescents, the most common age group is between 45 and 70 years of age and is 
not correlated with place of origin, race, and sex [7, 10–14].
3. Association with malignancy and genetic background
PNP can be triggered by several types of neoplasias; however, about 84% 
of all patients present neoplasias or hematological disorders [3, 7, 15]. Non-
Hodgkin’s lymphoma is the most common disorder with 38.6% of cases, fol-
lowed by chronic lymphocytic leukemia and Castleman disease with 18.4% 
each (Table 1). Among the non-hematological neoplasms, sarcomas present 
approximately 8.6% of the cases, such as leiomyosarcoma, malignant nerve 
sheath tumor, poorly differentiated sarcoma, reticular cell sarcoma, dendritic 
cell sarcoma, liposarcoma, and inflammatory myofibroblastoma [15–17]. Other 
less common diseases described in the literature that provide PNP are malignant 
thymoma, squamous cell carcinoma of the esophagus, colon carcinoma, CD8+ 
T-cell lymphoma, retroperitoneal Kaposi’s sarcoma, and lymphoepithelioma-like 
carcinoma [18–23]. Although the PNP is triggered by several neoplasias, the 
manifestations of this disease may precede the hematological disorders and other 
malignancies, thus requiring the frequent and continuous follow-up of these 
patients [15]. In addition, there are reports of the occurrence of PNP without a 
detecting the cause [24, 25].
It is known that the major histocompatibility complex (MHC) has important 
relationships in increasing the susceptibility of autoimmune diseases. Although 
there are few papers that analyze the relationship between PNP and genetics, 
some studies in the Caucasian and Chinese population showed the relationships 
of the HLA class II alleles DRB1*03 and HLA-Cw*14 in the PNP’s trigger [26, 27]. 
HLA-Cw* 14 proved to be a more specific allele type of PNP. Its importance has 
been associated with PNP, regardless of whether it is a Castleman disease or other 
tumors, in addition to Castleman disease. [26]. However, to date, these studies 
are preliminary studies that suggest the association between genetic factors and 
PNP. To better understand this relationship, it is important to conduct studies with 
larger numbers of patients and that are affected by different tumors, as well as the 
realization of this association in different populations.
Neoplasms Frequencies (%)
Non-Hodgkin’s lymphoma 38.6
Chronic lymphocytic leukemia 18.4
Castleman disease 18.4
Sarcoma 8.6
Others 16
Table 1. 
Paraneoplastic pemphigus associated with neoplasms.
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4. Pathogenesis
PNP even being a disease not yet known at the present time, it is known that 
both autoantibodies, as cell-mediated immunity, are involved [28]. Certainly, it 
deduces that the immune system is paramount in the pathophysiology of  
this disease.
4.1 Autoantibodies
PNP triggers immune changes with the production of autoantibodies capable of 
acting on various proteins in the body. The major target proteins of the autoanti-
bodies are desmoglein 1 (DSG-1) and desmoglein 3 (DSG-3); desmocollins 1, 2, and 
3; desmoplakins 1 and 2; BP230; BP130; and envoplakin, in addition to several other 
epitopes affected by autoantigens found in the individual [29]. These characteristics 
demonstrate the immunological complexity of the disease.
Proteins of the plakin family, such as desmoplakins 1 and 2, envoplakin, peri-
plakin, plectin and BP230, demonstrate the major targets of autoantibodies [30]. 
In contrast, the proteins of the cadherin family are the second most affected, with 
proteins such as DSG-1 and DSG-3 and desmocollin [31]. It is known that the pres-
ence of autoantibodies to some proteins are not related to the clinical practice of the 
patients, although there is a study that has mentioned DSG-3 relation with genital 
involvement [32].
Other autoantibodies such as alpha-2 macroglobulin-like 1 (A2ML1), a 
broad-range protease inhibitor, have been shown to be important in some 
patients. This protein has been shown to increase in the oral mucosa, intes-
tine, esophagus, and muscles. However, its true function in the epithelium is 
unknown [33, 34].
PNP studies with tumor resection demonstrate that tumors have the capac-
ity to secrete autoantibodies capable of affecting the proteins of the epidermal 
region [35]. While knowing that most PNPs are involved in neoplastic and LPD 
diseases, triggering by solid tumors is still poorly understood and demonstrates 
other mechanisms involved in the production of autoantibodies to plakin 
proteins.
The involvement of the humoral immunity of PNP presents the desmoplakins 1 
and 2, envoplakin, periplakin, BP230, A2ML1, and DSG-1 and DSG-3 as the main 
proteins of concern [1]. However, 16% of all affected do not demonstrate the pres-
ence of these autoantibodies, and this makes, in some cases, the accomplishment 
of the early diagnosis difficult. A study conducted in patients with PNP and who 
developed muscle weakness demonstrated autoantibodies against neuromuscular 
junction proteins and muscle tissue. These muscle-associated proteins were auto-
antibodies to anti-acetylcholinesterase receptors and anti-titin and anti-ryanodine 
receptor [36].
4.2 Cellular immunity
Cellular immunity has evidenced important roles in the immunophenotyping 
of PNP. Pathological analyses have demonstrated inflammatory infiltrates with the 
presence of CD8+ T cells, CD68+ monocytes, and non-major histocompatibility 
complex-restricted CD56+ in the subepidermal region [2, 37]. Besides that, in 
the places of affection, the increase in tumor necrosis factor, as well as interferon 
gamma, was evidenced [38]. These findings show the importance of cellular immu-
nity in the pathogenesis of the disease, since they present abundantly in the sites of 
PNP involvement.
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5. Clinical features
PNP presents several symptoms and clinical evolutions. The first symptoms as 
well as the progression of the disease are very varied from one patient to another. 
However, there are more frequent clinical features of these individuals.
5.1 Oral lesions
The oral mucosa is often affected in patients with PNP [3, 39, 40]. Oral symp-
toms may be the first symptoms in these patients, even before skin lesions [41]. 
The most common symptoms are oral and labial erosions with bleeding that may 
be associated with blisters, macules, papules, vesicles, and erythema (Figure 1). In 
addition, these patients may present a positive Nikolsky sign [41].
PNP lesions may be similar to oral manifestations of other diseases. Pemphigus 
vulgaris is a disease that initially triggers blisters and ulcers in the oral mucosa (espe-
cially on the cheeks) and may even reach the body. Erythema multiforme also affects 
the region of the oral mucosa with the appearance of erythema, edema, and some 
superficial erosions with formation of pseudomembrane. Lichen planus causes ery-
thematous lesions where Wickham striae are present and may in rare cases develop 
erosions. In most cases of oral lichen planus, these are asymptomatic manifestations 
with few complications. Even though these diseases show some similarity to PNP, 
they are less aggressive, lethal, painful, and incapacitating, with less ability to spread 
to all mucosal and other body sites when compared to PNP [28, 42, 43].
5.2 Secondary mucosal lesions
Lesions can also affect regions such as the oropharynx, esophagus, stomach, 
duodenum, large intestine, conjunctiva, and anogenital region [2, 3, 7, 39, 41, 
 44, 45]. The involvement of the oropharynx and esophagus commonly triggers 
painful sensations and dysphagia [4]. The anogenital lesions demonstrate red-violet 
erythema in the glans or its surroundings (Figure 2). In some cases, lichen planus 
presents a possible differential diagnosis. However, unlike red-violet lesions, lichen 
planus forms linear white streaks that may arise in the glans, scrotum, and vulva, 
in addition to the presence of dyspareunia and pruritus [43]. In these patients, both 
necrosis and loss of epidermis are absent, unlike patients with PNP who present this 
clinical [43].
Figure 1. 
Severe erosive mucositis with hematic crusting on the lips and oral mucosa.
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About 70% of the patients present conjunctival lesions such as bilateral bulbar 
conjunctival hyperemia, diffuse papillary tarsal conjunctival reactions, conjunctival 
epithelium desquamation, forniceal shortening, painful ocular irritation, poor vision, 
conjunctival and corneal erosions, and pseudomembranous conjunctivitis [2, 46, 47].
5.3 Skin lesions
Skin lesions usually appear soon after the onset of mucosal involvement [48]. 
The most affected sites are the dorsal region (Figure 3), head, and neck (Figure 4), 
in addition to the nearby extremities [4, 39, 49]. Patients with PNP started the study 
in very different ways, with the first signs being erythema, bullous and vesicular 
lesions, papules, skin scaling with Nikolsky sign, exfoliative erythema, and ulcers 
with hematic crust. Often, the first clinical sign on the skin is erythema that may 
progress with bullous and ulcerated lesions [24, 50]. Unlike adults, PNP in the skin 
of children appears in the form of lichenoid lesions, rather than bullous lesions.
Similar to PNP, bullous pemphigoid (BP) provides blistering with erythematous base 
or normal skin. However, BP lesions occur more frequently in the lower abdomen and 
lower limbs, and in most individuals, mucosal lesions are not affected [51]. In addition, 
pruritus is present in the vast majority of these patients, unlike PNP, which show painful 
and disseminated lesions mainly in the upper body and mucosal regions [28, 51].
Figure 2. 
Red-violet lesion in the genital organ.
Figure 3. 
Extensive erosions and blisters in the dorsal region.
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Already erythema multiforme shows prodromal symptoms such as fever and 
myalgia before the appearance of lesions on the mucosal and skin. Their skin lesions 
change in feature according to the course of the disease and resemble insect bites 
or hives that result in the well-known targetoid lesions that are common in this 
disease. Although cases of necrosis and blisters occur in the center of the lesions, 
this disease shows less aggression and fewer blisters and ulcers with hematic crusts 
than the patients affected by PNP [42].
Lichen planus affects flexor surfaces of the wrists, forearm, and legs. These 
lesions have round reticular white lines such as Wickham striae. They may arise in 
places that suffer trauma (Koebner’s phenomenon), in addition to making the site 
pigmented after inflation, thus demonstrating clinical differences in cutaneous 
erosions seen in the course of PNP progression [43].
The graft versus host disease causes rash and maculopapular rash that present 
itching and can spread to the entire body, less in the scalp. In very severe cases, there 
may be some sites with necrosis at the base of epidermal rete pegs [52]. Generally, 
these severe cases are differentiated from the PNP both by the patient’s clinical his-
tory and by skin biopsy that demonstrate distinct histopathological characteristics.
5.4 Pulmonary manifestations
Approximately 92.8% of the cases described in the literature show pulmonary 
involvement [3]. The pulmonary clinical signs of PNP are dyspnea, obstructive 
pulmonary disease, and bronchiolitis obliterans. The resolution of pulmonary 
problems is of extreme importance, since it is the main cause of death in individuals 
with PNP [53]. The patients with the greatest pulmonary involvement are Chinese 
children and patients with Castleman disease [53]. Studies show that 71% of the 
patients had bronchiolitis obliterans organizing pneumonia, and they give worse 
prognosis even if treatment of the neoplasia occurs [12, 54].
6. Histopathological examination
The pathological analyses demonstrate many varied aspects, since they show 
them peculiar characteristics according to the evaluated lesions [55]. When 
Figure 4. 
Confluent erosions with hematic crusts in the head and neck region.
7Paraneoplastic Pemphigus Is a Life-Threatening Disease
DOI: http://dx.doi.org/10.5772/intechopen.84956
analyzing the biopsy of blisters, we found acantholysis with inflammatory 
infiltrates (Figure 5) [55]. However, when it presents inflammatory maculo-
papular lesions, the most common findings are lichenoid interface dermatitis 
[55]. In the presence of lesions with the presence of blisters and maculopapular 
lesions, mixed characteristics of each type of lesion may occur in the pathol-
ogy. The findings with dyskeratosis and suprabasal acantholysis are one of the 
most important characteristics that lead to the definitive diagnosis of PNP [6]. 
Dyskeratosis is an abnormal formation of epidermal keratinization, whereas 
acantholysis is the loss of adhesion between skin cells [28]. These findings 
may help in the diagnosis even when there is no possibility of performing 
direct immunofluorescence (DIF) or when they are negative [39, 55]. DIF is a 
laboratory technique capable of detecting the deposition of autoantibodies and 
immune cells in the sites affected by the disease. The use of DIF demonstrates 
an extremely important technique for the diagnosis of PNP, since it can analyze 
both specific autoantibodies and cytotoxic cells of the human immune system, 
such as CD8+ T cells that act by attacking several layers with keratin and dem-
onstrating intracellular staining of cementum and/or marking of epidermal 
dermal junctions in band [28, 55].
7. Immunological studies
The use of DIF demonstrates great importance in the diagnosis of PNP even 
though approximately 50% of the cases show negative [3]. This technique shows a 
staining in IgG deposition intracellular chicken wire pattern (linear formation of 
autoantibodies deposition) along the dermoepidermal junction in both the linear 
form, as granulate [15]. The presence of IgG deposition in the dermoepidermal region 
is very characteristic of the PNP; however, only 25% presents this pattern [56].
The use of indirect immunofluorescence (IIF) shows involvement of the epider-
mis by the deposition of IgG in the intercellular regions. Other techniques used as 
cytoplasmic fluorescence (intracellular staining) demonstrate a prominent basal 
staining. IIF marking is extremely strong in the layers of the epithelium, and this, 
alerting to PNP investigation, since it shows high specificity [56].
Figure 5. 
Histopathological examination of the biopsy specimen showing keratinocyte apoptosis and 
acantholysis (hematoxylin and eosin, original magnification × 100).
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Other serological methods may also be used, such as immunoprecipitation, 
immunoblot and anti-EP enzyme-linked immunosorbent assay (ELISA) [57–59]. 
Studies evidenced 95 and 100% sensitivity in radioactive and nonradioactive 
immunoprecipitation techniques, respectively, and this demonstrates that immuno-
precipitation is the most serologically sensitive test for PNP diagnosis [57, 60, 61]. 
Currently the immunoprecipitation is considered gold standard in the diagnosis of 
PNP, that is, the main criterion to diagnose [62, 63].
8. Diagnosis
The criteria for diagnosis according to Anhalt et al. in 1990 are based on five 
criteria, such as clinical characteristics, histopathological analysis, direct and 
indirect immunofluorescence, and immunoprecipitation [1]. These criteria have 
been modified and adapted. In 1993, researchers included to perform the diagnosis 
the presence of three main criteria or two major and two minor [63]. Already in 
2002, Mimouni et al. reviewed the Anhalt criteria and considered four minimum 
criteria of high confidence in diagnosis (Table 2) [12]. DIF is a nonessential crite-
rion because of its low sensitivity. As for IIF on rat bladder epithelia and monkey 
esophagus, they were considered useful for tracking and detecting PNP [57, 64]. 
Negative IIF cannot exclude PNP, and other techniques such as immunoblotting and 
immunoprecipitation should be used to confirm or rule out a diagnosis.
9. Differential diagnosis
The diagnosis of PNP can be complex and difficult to perform because there are 
several similar diseases (Table 3). PNP and pemphigus vulgaris (PV) are very similar 
clinically, but some details differentiate them. PNP develops with inflammatory 
papules or macules that progress to blisters, while PV presents bullous lesions with a 
reddish background. Molecularly, the PNP presents some antibodies specific for this 
disease, such as the presence of anti-A2ML1, anti-envoplakin, and anti-periplakin, 
and demonstrates patterns of IgG deposition on cell surfaces with accumulation in 
the basement membrane zone [57, 64–66]. Even though bullous autoimmune diseases 
resemble each other, PNP differentiates it by the presence of antibody that stains the 
mouse bladder. In bullous pemphigoid (PB), BP230 and BP180 can be found, as well 
as in PNP. However, the use of DIF differentiates them by the IgG deposition patterns 
found in the PNP. The involvement by morbilliform-like erythema, toxic epidermal 
necrolysis, and Stevens-Johnson syndrome can also be confused with PNP. However, 
the detection of antibodies, pathological analysis of the lesions, and the patient’s clinic 
can differentiate these diseases [1, 10, 39, 57, 64–66].
Despite some cases that both clinically and histologically resemble each other, it 
is important to perform other techniques to rule out differential diagnoses. The use 
of otorhinolaryngological examination is very important to differentiate the diseases 
1. Clinical features of severe and protracted mucosal involvement and polymorphic cutaneous eruptions
2. Histologic features of acantholysis or lichenoid or interface dermatitis
3. Demonstration of antiplakin autoantibodies
4. The presence of an underlying neoplasm, especially lymphoproliferative tumors
Table 2. 
Minimum criteria for diagnosis.
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that affect the mucous membranes. Well-done physical examination of the oral cavity, 
histopathological analysis characteristics, cutaneous involvement, and the presence 
of IIF strongly suggest for the diagnosis of PNP [40, 44, 67].
10. Treatment
Effective treatment for PNP is still a major puzzle because of its rarity. Although 
several drugs are used in the literature, PNP has shown great resistance when compared 
to other forms of pemphigus [50, 68]. When there is suspicion or evidence of PNP, 
the performance of the six steps described on 2011 by Frew et al. may provide better 
management of individuals (Table 4) [69]. Stabilization of patients, according to the 
first step, is the most important step, since it is the major cause of death in patients [69].
Currently, the first-line treatment for PNP is still high doses of corticosteroids 
[70]. This treatment improves the cutaneous lesions, but the mucosal involvement 
is little altered. The use of other drugs also shows little efficacy in the lesions of the 
mucosa, this resistance being the characteristic of the disease [69, 71].
Several studies have shown that the combination of drugs has been effective 
and safe. These associations were prednisolone used with other therapies, such as 
mycophenolate mofetil, cyclosporine A, azathioprine, plasmapheresis, and intrave-
nous immunoglobulin [72–77]. Even though treatment is more effective, mucosal 
involvement is still resistant to such combined therapies [71].
The use of monoclonal antibody has been effective in the treatment of PNP in 
some case reports described in the literature. Administration of rituximab, an anti-
CD20, has shown good PNP therapy due to B-cell lymphoma [78, 79]. This therapy 
is based on an infusion of 375 mg/m2 weekly for 4 weeks followed by eight weekly 
infusions for 4 weeks of corticosteroid and administration of other immunosup-
pressive drugs such as cyclosporine A [69].
The use of alemtuzumab, a humanized monoclonal antibody that binds to CD52, 
has been reported. Reported in the treatment of PNP remission in patients whose 
presence of chronic lymphoid leukemia [80]. Alemtuzumab has been used in a patient 
with resistance to other drugs such as corticosteroids, intravenous immunoglobulin, 
Disease Causers Pathophysiology
Pemphigus 
vulgaris
Autoimmune reaction Autoantigens anti-desmoglein 1,3
Bullous 
pemphigoid
Autoimmune reaction Autoantigens anti-BP180 and anti-BP230
Lichen planus Autoimmune reaction Autoantigens anti-keratinocyte and 
antinuclear
Erythema 
multiforme
hypersensitivity by infection, 
viruses and drugs
Infiltration of cytotoxic T cell and increased 
tumor necrosis factor-α
Toxic epidermal 
necrolysis
Drug reaction that affects more 
than 30% of the body
Infiltration of cytotoxic T cell, natural killer, 
and increased granulysin
Stevens-Johnson 
syndrome
Drug reaction that affects less 
than 10% of the body
Infiltration of cytotoxic T cell, natural killer, 
and increased granulysin
Drug eruption Drug reaction Perivascular infiltration by lymphocytes, 
eosinophils, and increased histamine and 
leukotrienes
Table 3. 
Differential diagnosis.
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and cyclosporine A. In this patient, intravenous 30 mg was infused three times a week 
for 3 months. Even though there was improvement in both skin and mucosal lesions, 
the patient continued maintenance treatment with 500 mg of mycophenolate mofetil 
and 5 mg of prednisone [80]. Although there are several treatment alternatives, new 
therapies that reduce the resistance of PNP to drugs are still fundamental. Daclizumab, 
a monoclonal antibody against T-cell interleukin-2, has been shown to be a promising 
therapy [81].
It is known that in order to avoid large amounts of autoantibodies released into 
the bloodstream during tumor excision surgery, it is necessary to block blood flow 
and prevent compression of neoplastic tissue. In addition, the use of intravenous 
immunoglobulin before and during operations has demonstrated a significant 
reduction in mortality caused by bronchiolitis obliterans. Even after complete 
tumor resolution, immunoglobulin administration is required until 2 years to 
provide remission of autoimmunity triggered by PNP [82, 83].
In addition to the treatment of neoplasia and PNP, other ducts must be 
performed. When there is loss of skin integrity or immunosuppression, antimi-
crobial therapy is recommended early to prevent sepsis. Medications for pain 
control are also useful, since patients have pain in regions with ulceration and 
erosions [50].
Although there are several treatments stipulated in the literature, there are still 
no known drugs that reduce the mortality of patients, since the PNP proves highly 
resistant to more aggressive therapies. However, it is known that management, 
diagnosis, and early treatment are indispensable methods for a better response of 
the patients in the prescribed procedures.
11. Prognosis
The prognosis of PNP is extremely poor. Mortality can reach 90% of the cases 
in the first year, 41% of mortality in the second year, and 38% of death in the third 
year with the disease [84]. Commonly, death is triggered by systemic complications 
such as bronchiolitis obliterans, sepsis, and bleeding in the gastrointestinal tract 
[6, 50]. It is known that regardless of the cure or control of the neoplasia, the PNP 
progresses, demonstrating itself autonomous to the triggering factor [6, 10, 11, 
13, 50]. Patients who exhibit morbilliform erythema and necrosis of skin biopsy 
keratinocytes demonstrate a worse overall survival [84]. In some cases, the removal 
of Castleman disease and benign thymoma has shown better results than other 
underlying diseases [84, 85].
Even with a high mortality rate, the prognosis depends very much on the proper 
management of the patient, such as monitoring of vital signs, control of oral and 
skin lesions, treatment of the triggering disease, and prevention of sepsis and 
bronchitis obliterans. For this, it is essential to follow the patient closely and treat 
the disease aggressively [50].
1. Stabilization of vital parameters
2. Assessment of any underlying malignancy
3. Diagnosis of PNP
4. Removal and therapy for the triggering tumor
5. Treatment of PNP
Table 4. 
Management of the patient with suspected PNP.
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12. Quality of life
Studies have mentioned severe losses in the quality of life of patients with 
pemphigus. The main criteria that impair the quality of life were the greater severity 
of the disease, anxiety, and depression. However, there was no clear measurement 
of gender, age, type of pemphigus, duration of disease, skin involvement, disease 
activity, itching, burning sensation in the skin, or treatment in use [86]. There is 
still a great need in the standardization and validation of PNP-specific question-
naires, as this proves to be extremely important in order to know and enable actions 
at key points by multidisciplinary teams.
13. Conclusions
PNP demonstrates a great challenge for physicians, since it presents several clini-
cal aspects and varied degrees of bodily involvement. Early diagnosis, management 
of the patient, treatment of the underlying neoplasia, and aggressive treatment for 
PNP are of paramount importance for the best prognosis of the patient, since it is an 
extremely lethal disease. For this, more studies are needed to better understand the 
disease and cooperation between multidisciplinary teams involving dermatologists, 
oncologists, hematologists, otorhinolaryngologists, surgeons, ophthalmologists, 
immunologists, psychologists, nurses, and social workers.
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Appendices and nomenclature
A2ML1 alpha-2 macroglobulin-like 1
BP bullous pemphigoid
DIF direct immunofluorescence
DSG desmoglein
IIF indirect immunofluorescence
LPD lymphoproliferative disorders
PNP paraneoplastic pemphigus
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